STOCK TITAN

PAVmed Inc - PAVM STOCK NEWS

Welcome to our dedicated news page for PAVmed (Ticker: PAVM), a resource for investors and traders seeking the latest updates and insights on PAVmed.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PAVmed's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PAVmed's position in the market.

Rhea-AI Summary
Lucid Diagnostics Inc. (LUCD) announced that their President & COO will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference. The webcast will be available on their website, with a replay option for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
conferences
-
Rhea-AI Summary
PAVmed Inc. reports a 33% sequential increase in quarterly revenue and launches PMX incubator for technology development. Lucid Diagnostics Inc. shows revenue growth and expansion in clinical data evidence. Veris Health Inc. focuses on financing from academic and regional cancer centers. Financially, the company had a net loss but positive revenue growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Lucid Diagnostics Inc. (LUCD) reports a 33% sequential increase in Quarterly EsoGuard® revenue. The company is focused on expanding clinical validity and utility data to drive medical policy coverage, including potential Medicare coverage. Lucid's recent business update highlights revenue growth, stable test volume, improving revenue cycle management, and progress in engaging with major commercial payors for positive coverage.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.6%
Tags
Rhea-AI Summary
Lucid Diagnostics Inc. announces promising results from a VA screening study showing EsoGuard sensitivity of 92.9% and negative predictive value of 98.6% for esophageal precancer detection. The study highlights EsoGuard as a powerful screening tool for early detection of esophageal cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
PAVmed Inc. announces the launch of PMX incubator, in a joint venture with Hatch Medical, to advance PortIO Implantable Intraosseous Vascular Access Device and other technologies. The partnership aims to facilitate capital formation for development and commercialization, starting with PortIO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.07%
Tags
none
-
Rhea-AI Summary
Lucid Diagnostics Inc. (LUCD) and collaborators will present data on three studies on EsoGuard® esophageal precancer testing and one on a new genetic classifier of esophageal neoplasia at the Digestive Disease Week (DDW) Annual Meeting 2024. The studies aim to expand the clinical evidence base for EsoGuard testing to detect esophageal precancer and introduce a new genetic classifier.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
none
Rhea-AI Summary
PAVmed Inc. to host a business update conference call and webcast to discuss operations, growth strategy, and financial results for the fourth quarter and full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.6%
Tags
none
-
Rhea-AI Summary
Lucid Diagnostics Inc. (Nasdaq: LUCD) announced a business update conference call and webcast to discuss operational updates, growth strategy, and financial results for the fourth quarter and full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Lucid Diagnostics Inc. (Nasdaq: LUCD) received notification from the World Trade Center Health Program regarding a clerical error in listing the EsoGuard® Esophageal DNA test as a covered benefit. Lucid is actively engaging with Clinical Centers of Excellence to rectify the issue and ensure access to esophageal precancer testing for at-risk participants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Lucid Diagnostics Inc. highlights EsoCheck's advanced cell collection technology during testimony before the U.S. House of Representatives' Committee on Small Business. EsoCheck's innovative Collect & Protect® technology offers precise, noninvasive esophageal cell collection, leading to unprecedented early precancer detection results. The device's efficiency allows for high-volume testing events, with excellent patient satisfaction and DNA yields. In contrast, older 'sponge-on-a-string' technologies lack EsoCheck's precision and protection features, resulting in poor sensitivity and mechanical failures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
none
PAVmed Inc

Nasdaq:PAVM

PAVM Rankings

PAVM Stock Data

17.70M
8.08M
7.23%
12.4%
4.23%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
New York

About PAVM

pavmed is a groundbreaking medical device company bringing innovative medical technologies from concept to commercialization with unprecedented speed and efficiency. led by three accomplished medical device entrepreneurs and organized to conceive, develop and commercialize a diversified pipeline of innovative products we believe address unmet clinical needs, our goal is to enhance and accelerate value creation by employing a business model focused on capital and time efficiency.